The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 1811-1818

  Ooi, Esther M M ^a   Barrett, P Hugh R ^a,b   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Coronary artery disease; Familial hypercholesterolemia; Lipoprotein metabolism; Pharmacotherapies

Indexed keywords

ALIROCUMAB; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIACYLGLYCEROL ACYLTRANSFERASE 1; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOCKED NUCLEIC ACID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; PROBUCOL; RVX 208; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; THYROMIMETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CATABOLISM; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; NONHUMAN; OBESITY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; RISK FACTOR;

CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; PHARMACOTHERAPIES;

ANIMALS; CHOLINERGIC ANTAGONISTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIPOPROTEINS;

EID: 84885644881     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.069     Document Type: Review

References (134)

1. H.A. Neil, V. Seagroatt, and D.J. Betteridge Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia Heart 12 2004 1431 1437
2. M.A. Austin, C.M. Hutter, R.L. Zimmern, and S.E. Humphries Familial hypercholesterolemia and coronary heart disease: a HuGE association review Am J Epidemiol 5 2004 421 429
3. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group BMJ 6807 1991 893 896
4. J. Versmissen, D.M. Oosterveer, and M. Yazdanpanah Efficacy of statins in familial hypercholesterolaemia: a long term cohort study BMJ 2008 a2423
5. Z. Reiner, A.L. Catapano, and G. De Backer ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 14 2011 1769 1818
6. G.F. Watts, D.R. Sullivan, and N. Poplawski Familial hypercholesterolaemia: a model of care for Australasia Atheroscler Suppl 2 2011 221 263
7. M.A. Austin, C.M. Hutter, R.L. Zimmern, and S.E. Humphries Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review Am J Epidemiol 5 2004 407 420
8. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia The Molecular and Metabolic Basis of Inhabited Disease 1999 1981 2020
9. D.J. Rader, J. Cohen, and H.H. Hobbs Monogenic hypercholesterolemia: new insights in pathogenesis and treatment J Clin Invest 12 2003 1795 1803
10. A.K. Soutar, and R.P. Naoumova Mechanisms of disease: genetic causes of familial hypercholesterolemia Nat Clin Pract Cardiovasc Med 4 2007 214 225
11. D.C. Chan, and G.F. Watts Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box Metabolism 1 2012 3 11
12. M. Guerin Reverse cholesterol transport in familial hypercholesterolemia Curr Opin Lipidol 2012 377 385
13. M. Benn, G.F. Watts, A. Tybjaerg-Hansen, and B.G. Nordestgaard Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication J Clin Endocrinol Metab 11 2012 3956 3964
14. L.A. Neefjes, G.J. Ten Kate, and A. Rossi CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia Heart 14 2011 1151 1157
15. A. Vuorio, K.F. Docherty, S.E. Humphries, J. Kuoppala, and P.T. Kovanen Statin treatment of children with familial hypercholesterolemia - trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis 2013 315 320
16. G.R. Thompson, R.P. Naoumova, and G.F. Watts Role of cholesterol in regulating apolipoprotein B secretion by the liver J Lipid Res 3 1996 439 447
17. A.D. Sniderman, X.J. Zhang, and K. Cianflone Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm Atherosclerosis 2 2000 215 229
18. A.D. Sniderman, and K. Cianflone Substrate delivery as a determinant of hepatic apoB secretion Arterioscler Thromb 5 1993 629 636
19. P.H. Barrett, and G.F. Watts Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism Atheroscler Suppl 3 2002 1 4
20. R.K. Avramoglu, K. Cianflone, and A.D. Sniderman Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells J Lipid Res 12 1995 2513 2528
21. J.D. Horton, H. Shimano, R.L. Hamilton, M.S. Brown, and J.L. Goldstein Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL J Clin Invest 7 1999 1067 1076
22. J. Twisk, D.L. Gillian-Daniel, and A. Tebon The role of the LDL receptor in apolipoprotein B secretion J Clin Invest 4 2000 521 532
23. D.L. Gillian-Daniel, P.W. Bates, A. Tebon, and A.D. Attie Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B Proc Natl Acad Sci U S A 7 2002 4337 4342
24. D.A. Blasiole, A.T. Oler, and A.D. Attie Regulation of ApoB secretion by the low density lipoprotein receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB J Biol Chem 17 2008 11374 11381
25. M.A. Cayo, J. Cai, and A. Delaforest 'JD' iPS cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia Hepatology 2012 2163 2171
26. C.A. Hornick, T. Kita, R.L. Hamilton, J.P. Kane, and R.J. Havel Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits Proc Natl Acad Sci U S A 19 1983 6096 6100
27. J.S. Millar, C. Maugeais, I.V. Fuki, and D.J. Rader Normal production rate of apolipoprotein B in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 6 2002 989 994
28. E.D. Janus, A.M. Nicoll, P.R. Turner, P. Magill, and B. Lewis Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects Eur J Clin Invest 2 Pt 1 1980 161 172
29. W.R. Fisher, L.A. Zech, and P.W. Stacpoole ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm Arterioscler Thromb 4 1994 501 510
30. M.H. Cummings, G.F. Watts, and M. Umpleby Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study Atherosclerosis 1 1995 79 89
31. H. Zulewski, R. Ninnis, A.R. Miserez, M.W. Baumstark, and U. Keller VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100 J Lipid Res 2 1998 380 387
32. A.J. Tremblay, B. Lamarche, and I.L. Ruel Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation J Lipid Res 5 2004 866 872
33. J.S. Millar, C. Maugeais, and K. Ikewaki Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production Arterioscler Thromb Vasc Biol 3 2005 560 565
34. G.R. Thompson, T. Spinks, A. Ranicar, and N.B. Myant Non-steady-state studies of low-density-liproprotein turnover in familial hypercholesterolaemia Clin Sci Mol Med 4 1977 361 369
35. M. Pfohl, R.P. Naoumova, and C. Neuwirth Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect Atherosclerosis 2 1997 257 262
36. K.G. Parhofer, P.H. Barrett, T. Demant, W.O. Richter, and P. Schwandt Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia J Lipid Res 11 1996 2383 2393
37. P.H. Barrett, and K.G. Parhofer Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics Metabolism 4 1998 478 483
38. J. Pietzsch, B. Wiedemann, and U. Julius Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach J Lipid Res 10 1996 2074 2087
39. J.R. Schaefer, H. Scharnagl, and M.W. Baumstark Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs Arterioscler Thromb Vasc Biol 2 1997 348 353
40. K. Ouguerram, M. Chetiveaux, and Y. Zair Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9 Arterioscler Thromb Vasc Biol 8 2004 1448 1453
41. H. Tada, M.A. Kawashiri, and K. Ikewaki Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo Circ Cardiovasc Genet 1 2012 35 41
42. J. Hoover-Plow, and M. Huang Lipoprotein(a) metabolism: potential sites for therapeutic targets Metabolism 62 4 2013 Apr 479 491
43. B.G. Nordestgaard, M.J. Chapman, and K. Ray Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 23 2010 2844 2853
44. A.C. Jansen, E.S. Aalst-Cohen, and M.W. Tanck The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients J Intern Med 6 2004 482 490
45. P.N. Hopkins, S. Stephenson, and L.L. Wu Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia Am J Cardiol 5 2001 547 553
46. M. Seed, F. Hoppichler, and D. Reaveley Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia N Engl J Med 21 1990 1494 1499
47. M.S. Nenseter, H.W. Lindvig, and T. Ueland Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia Atherosclerosis 2 2011 426 432
48. H.G. Kraft, A. Lingenhel, F.J. Raal, M. Hohenegger, and G. Utermann Lipoprotein(a) in homozygous familial hypercholesterolemia Arterioscler Thromb Vasc Biol 2 2000 522 528
49. B.L. Knight, Y.F. Perombelon, A.K. Soutar, D.P. Wade, and M. Seed Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects Atherosclerosis 2-3 1991 227 237
50. Y.F. Perombelon, J.J. Gallagher, N.B. Myant, A.K. Soutar, and B.L. Knight Lipoprotein(a) in subjects with familial defective apolipoprotein B100 Atherosclerosis 2-3 1992 203 212
51. R. Liu, K. Saku, and G.M. Kostner In vivo kinetics of lipoprotein(a) in homozygous Watanabe heritable hyperlipidaemic rabbits Eur J Clin Invest 9 1993 561 565
52. M.A. Lasuncion, J.L. Teruel, and J.J. Alvarez Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis Eur J Clin Invest 12 1993 819 826
53. M.J. Chapman, H.N. Ginsberg, and P. Amarenco Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 11 2011 1345 1361
54. B.G. Nordestgaard, and J.J. Freiberg Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol Curr Vasc Pharmacol 3 2011 281 286
55. G.D. Kolovou, D.P. Mikhailidis, and J. Kovar Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement Curr Vasc Pharmacol 3 2011 258 270
56. C. Mihas, G.D. Kolovou, and D.P. Mikhailidis Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis Curr Vasc Pharmacol 3 2011 271 280
57. P.R. Sauvage Nolting, J.C. Defesche, and R.J. Buirma Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia J Intern Med 2 2003 161 168
58. G.D. Kolovou, P.M. Kostakou, and K.K. Anagnostopoulou Familial hypercholesterolemia and triglyceride metabolism Int J Cardiol 3 2011 349 358
59. H. Tada, M. Kawashiri, and A. Tanaka Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia Eur J Clin Invest 2012 1094 1099
60. M.E. Wittekoek, S.N. Pimstone, and P.W. Reymer A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia Circulation 8 1998 729 735
61. C.T. Johansen, S. Kathiresan, and R.A. Hegele Genetic determinants of plasma triglycerides J Lipid Res 2 2011 189 206
62. P.J. Talmud, S. Shah, and R. Whittall Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study Lancet 381 9874 2013 Apr 13 1293 1301
63. A. Varbo, M. Benn, and A. Tybjaerg-Hansen Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 2013 427 436
64. L. Berglund, J.D. Brunzell, and A.C. Goldberg Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 9 2012 2969 2989
65. M. Miller, N.J. Stone, and C. Ballantyne Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 20 2011 2292 2333
66. J.T. Real, F.J. Chaves, and I. Martinez-Uso Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia Eur Heart J 6 2001 465 471
67. V. Kozich, M. Janosik, and J. Sokolova Analysis of CBS alleles in Czech and Slovak patients with homocystinuria: report on three novel mutations E176K, W409X and 1223 + 37 del99 J Inherit Metab Dis 3 1997 363 366
68. D.M. Seo, and P.J. Goldschmidt-Clermont Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment Expert Rev Mol Diagn 1 2007 45 51
69. M.Y. Tsai, B.G. Welge, and N.Q. Hanson Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases Atherosclerosis 1 1999 163 170
70. J.F. Carlquist, J.B. Muhlestein, and B.D. Horne The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease Am Heart J 6 2003 1007 1014
71. M.F. Mohrschladt, van der Sman-de Beer, and M.K. Hofman TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia Eur J Hum Genet 7 2005 877 882
72. R. Frenais, K. Ouguerram, and C. Maugeais Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study J Lipid Res 8 1999 1506 1511
73. J.R. Schaefer, K. Winkler, and H. Schweer Increased production of HDL ApoA-I in homozygous familial defective ApoB-100 Arterioscler Thromb Vasc Biol 7 2000 1796 1799
74. J.C. Hogue, B. Lamarche, and D. Gaudet Association of heterozygous familial hypercholesterolemia with smaller HDL particle size Atherosclerosis 2 2007 429 435
75. K. Saku, K. Yamamoto, and T. Sakai Kinetics of HDL-apo A-I in the WHHL rabbit, an animal model of familial hypercholesterolemia Atherosclerosis 2-3 1989 225 230
76. J.R. Schaefer, D.J. Rader, and K. Ikewaki In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia Arterioscler Thromb 7 1992 843 848
77. N. Bellanger, A. Orsoni, and Z. Julia Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia Arterioscler Thromb Vasc Biol 7 2011 1675 1681
78. B.J. Ansell, K.E. Watson, A.M. Fogelman, M. Navab, and G.C. Fonarow High-density lipoprotein function recent advances J Am Coll Cardiol 10 2005 1792 1798
79. A. Orsoni, E.F. Villard, and E. Bruckert Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia J Lipid Res 4 2012 767 775
80. R. Huijgen, E.J. Abbink, and E. Bruckert Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial Clin Ther 4 2010 615 625
81. D.W. Bilheimer, S.M. Grundy, M.S. Brown, and J.L. Goldstein Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983 Atheroscler Suppl 3 2004 61 65
82. B. Sjouke, D.M. Kusters, J.J. Kastelein, and G.K. Hovingh Familial hypercholesterolemia: present and future management Curr Cardiol Rep 6 2011 527 536
83. P.N. Hopkins Familial hypercholesterolemia - improving treatment and meeting guidelines Int J Cardiol 1 2003 13 23
84. M.J. Koren, R. Scott, and J.B. Kim Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 9858 2012 1995 2006
85. E.A. Stein, S. Mellis, and G.D. Yancopoulos Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 12 2012 1108 1118
86. C.S. Dias, A.J. Shaywitz, and S.M. Wasserman Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins J Am Coll Cardiol 19 2012 1888 1898
87. F. Raal, R. Scott, and R. Somaratne Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial Circulation 20 2012 2408 2417
88. M.J. Graham, K.M. Lemonidis, and C.P. Whipple Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice J Lipid Res 4 2007 763 767
89. N. Gupta, N. Fisker, and M.C. Asselin A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo PLoS One 5 2010 e10682
90. M.W. Lindholm, J. Elmen, and N. Fisker PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates Mol Ther 2 2012 376 381
91. M. Frank-Kamenetsky, A. Grefhorst, and N.N. Anderson Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Proc Natl Acad Sci U S A 33 2008 11915 11920
92. L. Shan, L. Pang, and R. Zhang PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide Biochem Biophys Res Commun 1 2008 69 73
93. N.G. Seidah, and A. Prat The biology and therapeutic targeting of the proprotein convertases Nat Rev Drug Discov 5 2012 367 383
94. W. Xu, L. Liu, and D. Hornby c-IAP1 binds and processes PCSK9 protein: linking the c-IAP1 in a TNF-alpha pathway to PCSK9-mediated LDLR degradation pathway Molecules 10 2012 12086 12101
95. Y.G. Luna Saavedra, R. Day, and N.G. Seidah The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway J Biol Chem 2012 43492 43501
96. D. Sullivan, A.G. Olsson, and R. Scott Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 2012 1 10
97. B. Herbert, D. Patel, and S.N. Waddington Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control Arterioscler Thromb Vasc Biol 7 2010 1333 1339
98. F.J. Raal, and R.D. Santos Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment Atherosclerosis 2 2012 262 268
99. A.K. Soutar Unexpected roles for PCSK9 in lipid metabolism Curr Opin Lipidol 3 2011 192 196
100. F.J. Raal, V. Panz, A. Immelman, and G. Pilcher Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy J Am Heart Assoc 2 2013 e000028
101. N. Zelcer, C. Hong, R. Boyadjian, and P. Tontonoz LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor Science 5936 2009 100 104
102. E.A. Stein, R. Dufour, and C. Gagne Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 19 2012 2283 2292
103. M.E. Visser, G. Wagener, and B.F. Baker Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial Eur Heart J 9 2012 1142 1149
104. M. Cuchel, L.T. Bloedon, and P.O. Szapary Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 2 2007 148 156
105. M. Cuchel, E.A. Meagher, and T.H. du Toit Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 9860 2013 40 46
106. L.A. Carlson, A. Hamsten, and A. Asplund Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid J Intern Med 4 1989 271 276
107. A.E. Bochem, J.A. Kuivenhoven, and E.S. Stroes The promise of Cholesteryl Ester Transfer Protein (CETP) inhibition in the treatment of cardiovascular disease Curr Pharm Des 19 17 2013 3143 3149
108. P.W. Ladenson, J.D. Kristensen, and E.C. Ridgway Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N Engl J Med 10 2010 906 916
109. E. Merki, M. Graham, and A. Taleb Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice J Am Coll Cardiol 15 2011 1611 1621
110. E.D. Michos, C.T. Sibley, J.T. Baer, M.J. Blaha, and R.S. Blumenthal Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials J Am Coll Cardiol 23 2012 2058 2064
111. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 24 2011 2255 2267
112. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 17 2013 May 1279 1291
113. J. Bosch, H.C. Gerstein, and G.R. Dagenais n - 3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 4 2012 309 318
114. D. Kromhout, E.J. Giltay, and J.M. Geleijnse n - 3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 21 2010 2015 2026
115. A. Macchia, H. Grancelli, and S. Varini Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial J Am Coll Cardiol 4 2012 463 468
116. D. Mozaffarian, R. Marchioli, and A. Macchia Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial JAMA 19 2012 2001 2011
117. M. Yokoyama, H. Origasa, and M. Matsuzaki Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 9567 2007 1090 1098
118. T.H. Johannsen, R. Frikke-Schmidt, J. Schou, B.G. Nordestgaard, and A. Tybjaerg-Hansen Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects J Am Coll Cardiol 20 2012 2041 2048
119. S. Kunnen, and M. Van Eck Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis? J Lipid Res 9 2012 1783 1799
120. T.R. Joy Novel HDL-based therapeutic agents Pharmacol Ther 1 2012 18 30
121. D. Bailey, R. Jahagirdar, and A. Gordon RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 23 2010 2580 2589
122. A. Hovland, S. Marcovina, and R. Hardersen Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles Transfus Apher Sci 1 2012 73 76
123. G.R. Thompson Recommendations for the use of LDL apheresis Atherosclerosis 2 2008 247 255
124. H. Borberg 26 years of LDL-apheresis: a review of experience Transfus Apher Sci 1 2009 49 59
125. L.C. Hemphill Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis J Clin Lipidol 5 2010 346 349
126. E. Sondergaard, I. Rahbek, and L.P. Sorensen Effects of exercise on VLDL-triglyceride oxidation and turnover Am J Physiol Endocrinol Metab 5 2011 E939 E944
127. F.M. Riches, G.F. Watts, and J. Hua Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men J Clin Endocrinol Metab 8 1999 2854 2861
128. J.S. Rana, A.C. Jansen, and A.H. Zwinderman Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia Diabetes Care 5 2006 1125 1127
129. S. Yamashita, and Y. Matsuzawa Where are we with probucol: a new life for an old drug? Atherosclerosis 1 2009 16 23
130. R. Stocker Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues Curr Opin Lipidol 3 2009 227 235
131. M. Inagaki, Y. Nakagawa-Toyama, and M. Nishida Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia J Atheroscler Thromb 7 2012 643 656
132. D. Steinberg Studies on the mechanism of action of probucol Am J Cardiol 16 1986 16H 21H
133. P.J. Nestel, and T. Billington Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis Atherosclerosis 1-2 1981 203 209
134. S. Yamashita, H. Hbujo, and H. Arai Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan J Atheroscler Thromb 6 2008 292 303